$2.64 Billion is the total value of Tekla Capital Management LLC's 214 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRK | Merck & Co., Inc. | $110,175,000 | +8.0% | 1,211,384 | 0.0% | 4.17% | -6.3% | |
| MYL | Mylan N.V.shares | $20,875,000 | +1.6% | 1,038,554 | 0.0% | 0.79% | -11.9% | |
| PRAH | PRA Health Sciences, Inc. | $17,006,000 | +12.0% | 153,003 | 0.0% | 0.64% | -2.9% | |
| AZN | AstraZeneca PLCsponsored adr | $13,766,000 | +11.9% | 276,098 | 0.0% | 0.52% | -3.0% | |
| ESPR | Esperion Therapeutics, Inc. | $12,735,000 | +62.7% | 213,562 | 0.0% | 0.48% | +40.9% | |
| IMMU | Immunomedics, Inc. | $10,307,000 | +59.6% | 487,103 | 0.0% | 0.39% | +38.3% | |
| SBRA | Sabra Health Care REIT, Inc. | $9,950,000 | -7.1% | 466,247 | 0.0% | 0.38% | -19.5% | |
| TEVA | Teva Pharmaceutical Industries Limitedsponsored adr | $7,701,000 | +42.4% | 785,851 | 0.0% | 0.29% | +23.3% | |
| STRO | Sutro Biopharma, Inc. | $7,054,000 | +21.0% | 641,268 | 0.0% | 0.27% | +5.1% | |
| AVDL | Avadel Pharmaceuticals Public Limited Companysponsored adr | $6,150,000 | +81.5% | 814,588 | 0.0% | 0.23% | +57.4% | |
| NKTR | Nektar Therapeutics | $6,123,000 | +18.5% | 283,679 | 0.0% | 0.23% | +3.1% | |
| ABMD | ABIOMED, Inc. | $5,581,000 | -4.1% | 32,716 | 0.0% | 0.21% | -16.9% | |
| LH | Laboratory Corporation of America Holdingssponsored adr | $5,316,000 | +0.7% | 31,424 | 0.0% | 0.20% | -12.6% | |
| PIRS | Pieris Pharmaceuticals, Inc. | $5,246,000 | +6.2% | 1,449,269 | 0.0% | 0.20% | -8.3% | |
| XNCR | Xencor, Inc. | $5,098,000 | +2.0% | 148,231 | 0.0% | 0.19% | -11.5% | |
| UTHR | United Therapeutics Corporationclass b | $4,765,000 | +10.5% | 54,094 | 0.0% | 0.18% | -4.3% | |
| RCKT | Rocket Pharmaceuticals, Inc. | $4,724,000 | +95.4% | 207,555 | 0.0% | 0.18% | +70.5% | |
| XLRN | Acceleron Pharma Inc. | $4,576,000 | +34.2% | 86,313 | 0.0% | 0.17% | +16.1% | |
| ACHC | Acadia Healthcare Company, Inc. | $4,525,000 | +6.9% | 136,200 | 0.0% | 0.17% | -7.6% | |
| EDIT | Editas Medicine, Inc. | $4,380,000 | +30.2% | 147,939 | 0.0% | 0.17% | +12.9% | |
| ICPT | Intercept Pharmaceuticals, Inc. | $4,265,000 | +86.7% | 34,414 | 0.0% | 0.16% | +61.0% | |
| TAK | Takeda Pharmaceutical Company Limitedsponsored ads | $4,146,000 | +14.7% | 210,146 | 0.0% | 0.16% | -0.6% | |
| RARE | Ultragenyx Pharmaceutical Inc. | $4,163,000 | -0.2% | 97,480 | 0.0% | 0.16% | -13.7% | |
| ALKS | Alkermes Public Limited Companyshares | $4,040,000 | +4.6% | 198,048 | 0.0% | 0.15% | -9.5% | |
| INSM | Insmed Incorporated | $3,935,000 | +35.4% | 164,786 | 0.0% | 0.15% | +17.3% | |
| FATE | Fate Therapeutics, Inc. | $3,242,000 | +26.0% | 165,672 | 0.0% | 0.12% | +9.8% | |
| ALC | Alcon Inc.ordinary shares | $3,132,000 | -2.9% | 55,369 | 0.0% | 0.12% | -16.3% | |
| RARX | Ra Pharmaceuticals, Inc. | $2,620,000 | +98.5% | 55,829 | 0.0% | 0.10% | +70.7% | |
| PACB | Pacific Biosciences of California, Inc. | $2,547,000 | -0.4% | 495,495 | 0.0% | 0.10% | -14.3% | |
| QTNT | Quotient Limited | $2,473,000 | +22.4% | 260,030 | 0.0% | 0.09% | +6.8% | |
| ENDP | Endo International plcshares | $2,493,000 | +46.1% | 531,570 | 0.0% | 0.09% | +27.0% | |
| HQY | HealthEquity, Inc. | $2,356,000 | +29.6% | 31,810 | 0.0% | 0.09% | +12.7% | |
| HOLX | Hologic, Inc. | $2,229,000 | +3.4% | 42,701 | 0.0% | 0.08% | -10.6% | |
| EVH | Evolent Health, Inc. | $2,091,000 | +25.9% | 231,027 | 0.0% | 0.08% | +9.7% | |
| PHG | Koninklijke Philips N.V.ny reg sh | $2,084,000 | +5.8% | 42,700 | 0.0% | 0.08% | -8.1% | |
| CLLS | Cellectissponsored adr | $1,886,000 | +64.6% | 110,147 | 0.0% | 0.07% | +42.0% | |
| PKI | PerkinElmer, Inc. | $1,846,000 | +14.0% | 19,011 | 0.0% | 0.07% | -1.4% | |
| AERI | Aerie Pharmaceuticals, Inc. | $1,612,000 | +25.7% | 66,688 | 0.0% | 0.06% | +8.9% | |
| VRNA | Verona Pharma plcsponsored adr | $1,581,000 | +25.8% | 275,000 | 0.0% | 0.06% | +9.1% | |
| BHVN | Biohaven Pharmaceutical Holding Company Ltd. | $1,586,000 | +30.5% | 29,125 | 0.0% | 0.06% | +13.2% | |
| OVID | Ovid Therapeutics Inc.sponsored adr | $1,547,000 | +28.1% | 372,733 | 0.0% | 0.06% | +11.3% | |
| ZLAB | Zai Lab Limitedadr | $1,561,000 | +28.6% | 37,523 | 0.0% | 0.06% | +11.3% | |
| ACIU | AC Immune SAshares | $1,464,000 | +72.2% | 171,813 | 0.0% | 0.06% | +48.6% | |
| MYOK | MyoKardia, Inc. | $1,407,000 | +39.9% | 19,300 | 0.0% | 0.05% | +20.5% | |
| HTA | Healthcare Trust of America, Inc. | $1,393,000 | +3.1% | 46,000 | 0.0% | 0.05% | -10.2% | |
| ARNA | Arena Pharmaceuticals, Inc. | $1,272,000 | -0.8% | 28,002 | 0.0% | 0.05% | -14.3% | |
| SNR | New Senior Investment Group Inc. | $1,209,000 | +14.5% | 158,047 | 0.0% | 0.05% | 0.0% | |
| MDGL | Madrigal Pharmaceuticals, Inc. | $1,215,000 | +5.7% | 13,340 | 0.0% | 0.05% | -8.0% | |
| FOMX | Foamix Pharmaceuticals Ltdshares | $1,002,000 | +9.6% | 300,781 | 0.0% | 0.04% | -5.0% | |
| IMGN | ImmunoGen, Inc. | $859,000 | +111.1% | 168,190 | 0.0% | 0.03% | +77.8% | |
| NTLA | Intellia Therapeutics, Inc. | $808,000 | +9.9% | 55,050 | 0.0% | 0.03% | -3.1% | |
| ZYME | Zymeworks Inc. | $691,000 | +83.3% | 15,192 | 0.0% | 0.03% | +62.5% | |
| PBYI | Puma Biotechnology, Inc. | $624,000 | -18.8% | 71,340 | 0.0% | 0.02% | -29.4% | |
| CDTX | Cidara Therapeutics, Inc. | $610,000 | +92.4% | 158,784 | 0.0% | 0.02% | +64.3% | |
| CYH | Community Health Systems, Inc. | $591,000 | -19.5% | 203,935 | 0.0% | 0.02% | -31.2% | |
| PRGO | Perrigo Company Public Limited Companyshares | $559,000 | -7.6% | 10,818 | 0.0% | 0.02% | -19.2% | |
| MYGN | Myriad Genetics, Inc. | $512,000 | -4.8% | 18,805 | 0.0% | 0.02% | -17.4% | |
| CLSD | Clearside Biomedical, Inc. | $479,000 | +360.6% | 165,330 | 0.0% | 0.02% | +260.0% | |
| Trillium Therapeutics Inc. | $459,000 | +235.0% | 446,099 | 0.0% | 0.02% | +183.3% | ||
| SPPI | Spectrum Pharmaceuticals, Inc. | $417,000 | -56.2% | 114,670 | 0.0% | 0.02% | -61.0% | |
| MGTA | Magenta Therapeutics, Inc. | $254,000 | +47.7% | 16,757 | 0.0% | 0.01% | +25.0% | |
| ABIO | ARCA biopharma, Inc. | $206,000 | +7.3% | 36,068 | 0.0% | 0.01% | 0.0% | |
| CBAY | CymaBay Therapeutics, Inc. | $173,000 | -61.6% | 88,102 | 0.0% | 0.01% | -65.0% | |
| ARPO | Aerpio Pharmaceuticals, Inc. | $161,000 | -8.0% | 257,554 | 0.0% | 0.01% | -25.0% | |
| MNKKQ | Mallinckrodt public limited companysponsored adr | $115,000 | +45.6% | 32,980 | 0.0% | 0.00% | +33.3% | |
| NVAX | Novavax, Inc. | $114,000 | -20.3% | 28,550 | 0.0% | 0.00% | -33.3% | |
| BLCM | Bellicum Pharmaceuticals, Inc. | $77,000 | +22.2% | 60,000 | 0.0% | 0.00% | 0.0% | |
| ADAP | Adaptimmune Therapeutics plcsponsored adr | $92,000 | -20.7% | 77,061 | 0.0% | 0.00% | -40.0% | |
| QHCCQ | Quorum Health Corporation | $23,000 | -20.7% | 23,725 | 0.0% | 0.00% | 0.0% | |
| CLDX | Celldex Therapeutics, Inc. | $16,000 | +6.7% | 7,053 | 0.0% | 0.00% | 0.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Gilead Sciences, Inc. | 41 | Q2 2023 | 12.4% |
| Amgen, Inc. | 41 | Q2 2023 | 5.8% |
| Biogen Inc. | 41 | Q2 2023 | 6.5% |
| Vertex Pharmaceuticals Incorporated | 41 | Q2 2023 | 5.3% |
| Regeneron Pharmaceuticals, Inc. | 41 | Q2 2023 | 9.1% |
| Illumina, Inc. | 41 | Q2 2023 | 3.4% |
| BioMarin Pharmaceutical Inc. | 41 | Q2 2023 | 2.9% |
| Teva Pharmaceutical Industries Ltd. | 41 | Q2 2023 | 3.2% |
| Neurocrine Biosciences, Inc. | 41 | Q2 2023 | 1.4% |
| McKesson Corporation | 41 | Q2 2023 | 2.2% |
View Tekla Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rallybio Corp | January 23, 2023 | 1,727,067 | 4.6% |
| Zyla Life SciencesSold out | January 29, 2021 | 0 | 0.0% |
| ARCA biopharma, Inc. | January 24, 2020 | 36,068 | 2.3% |
| Verona Pharma plc | February 12, 2019 | 5,296,845 | 4.9% |
| Alliqua BioMedical, Inc. | February 12, 2018 | 165,000 | 3.3% |
| PIERIS PHARMACEUTICALS, INC. | February 12, 2018 | 1,962,380 | 4.4% |
| Intellipharmaceutics International Inc. | February 13, 2015 | 2,184,000 | 9.0% |
| HERON THERAPEUTICS, INC. /DE/ | February 14, 2014 | 20,598,613 | 4.2% |
| MEDWAVE INC | February 14, 2012 | 1,277,372 | 9.8% |
| MZT Holdings, Inc. | February 14, 2012 | 2,553,420 | 4.0% |
View Tekla Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-10 |
| SC 13G/A | 2023-01-23 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-29 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| SC 13G | 2022-01-21 |
| 13F-HR | 2021-11-12 |
View Tekla Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.